Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | LTX-315 |
| Trade Name | |
| Synonyms | Ruxotemitide |
| Drug Descriptions |
Ruxotemitide (LTX-315) is a 9-mer oncolytic peptide that induces release of danger-associated molecular pattern molecules (DAMPs), and may increase anti-tumor immune response and decrease tumor growth (PMID: 26982623, PMID: 30670061, PMID: 32258289). |
| DrugClasses | |
| CAS Registry Number | 1345407-05-7 |
| NCIT ID | C90547 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| LTX-315 | LTX-315 | 0 | 1 |
| LTX-315 + Pegylated liposomal doxorubicin | LTX-315 Pegylated liposomal doxorubicin | 0 | 0 |
| LTX-315 + Pembrolizumab | LTX-315 Pembrolizumab | 0 | 1 |